On June 25, Argenx SE rose 4.21% in regular trading, trading near $887.71/share, with turnover of approximately $236 million. The rally was driven by BNP Paribas initiating coverage on Argenx with an Outperform rating and a $1,219 price target, implying approximately 37% upside from current levels.

The BNP Paribas target significantly exceeds the analyst consensus mean target of $1,064.53, according to FactSet data, providing a sustained boost to market sentiment. The bullish thesis is further supported by strong fundamental developments: the company's core product Vyvgart secured FDA approval in May to expand its label to all serotypes of adult generalized myasthenia gravis patients, and first-quarter EPS of $5.52 beat the consensus estimate of $5.42, representing a 114% year-over-year increase.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)